Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 4/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL710096 | 0.88 | PTGDR2 (0.39) | AKR1C3AKR1C2PTGDR2PTGS2PTGS1 | |
| SCHEMBL27842486 | 0.84 | PTGS2 (0.41) | AKR1C3AKR1C2PTGDR2PTGS2PTGS1 | |
| SCHEMBL27823505 | 0.84 | PTGDR2 (0.44) | AKR1C3AKR1C2PTGDR2PTGS2PTGS1 | |
| SCHEMBL13354101 | 0.80 | PTGS1 (0.37) | AKR1C3AKR1C2PTGDR2PTGS2PTGS1 | |
| SCHEMBL709910 | 0.79 | PTGDR2 (0.54) | AKR1C3AKR1C2PTGDR2PTGS2PTGS1 | |
| SCHEMBL10374155 | 0.77 | AKR1C3 (0.51) | AKR1C3AKR1C2PTGDR2PTGS2PTGS1 | |
| SCHEMBL10374072 | 0.76 | AKR1C3 (0.50) | AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL709951 | 0.74 | PTGDR2 (0.44) | AKR1C3AKR1C2PTGDR2PTGS2PTGS1 | |
| SCHEMBL27842431 | 0.74 | PTGS2 (0.42) | PTGDR2PTGS2PTGS1ESR1 | |
| SCHEMBL11460496 | 0.73 | AKR1B1 (0.47) | AKR1C3AKR1C2PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | claimed |
| CN-102216249-A | Naphthylacetic acids | HOFFMANN LA ROCHE | 2011-10-12 | — | — | CN | claimed |
| EP-2346807-A1 | NAPHTHYLACETIC ACIDS | F. Hoffmann-La Roche AG (CH) | 2011-07-27 | — | — | EP | claimed |
| US-20100137250-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-06-03 | — | — | US | claimed |
| WO-2010055005-A1 | NAPHTHYLACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | claimed |
| US-8124629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| CN-102216249-A | Naphthylacetic acids | HOFFMANN LA ROCHE | 2011-10-12 | — | — | CN | disclosed |
| EP-2346807-A1 | NAPHTHYLACETIC ACIDS | F. Hoffmann-La Roche AG (CH) | 2011-07-27 | — | — | EP | disclosed |
| US-20100137250-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-06-03 | — | — | US | disclosed |
| US-20100137250-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-06-03 | — | — | US | disclosed |
| US-20100137250-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-06-03 | — | — | US | disclosed |
| WO-2010055005-A1 | NAPHTHYLACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010055005-A1 | NAPHTHYLACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137250-A1 | NAPHTHYLACETIC ACIDS | HRH2, HRH1, HRH3 | AKR1C3 120/4885AKR1C2 184/4885PTGDR2 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.